Remdesivir for the Treatment of COVID-19, its Safety and Clinical Effectiveness: A Clinical Review
Kimberly Morton Cuthrell *
Saint James School of Medicine, Illinois, United States of America.
Saima Batool
Nishtar Medical University, Pakistan.
Tayyab Khurshid
University of Veterinary and Animal Sciences, Lahore, Pakistan.
*Author to whom correspondence should be addressed.
Abstract
Remdesivir is a nucleotide analog pro-drug and antiviral medicine with broad spectrum effectiveness against viruses from several families. After exhibiting strong antiviral activity against coronaviruses in preclinical studies, remdesivir was approved as a specific drug for the treatment of the novel coronavirus disease 2019 (COVID-19), which was caused by the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the current global pandemic. The Remdesivir COVID-19 phase III evaluation began in early 2020, and preliminary findings are promising. For people with severe COVID-19, Taiwan temporarily approved the use of Remdesivir in late May 2020. The approval was quickly followed by a number of conditional permits in many countries/regions, including the United States of America (USA) and Canada. Remdesivir had already been granted emergency use authorization in the USA on May 1, 2020 and special authorization for emergency use in Japan on May 7, 2020. This article provides a summary of remdesivir's development and the significant events that led to its initial conditional approval for the treatment of COVID-19.
Keywords: Covid-19, remdesivir, pro-drug, antiviral, SARS-CoV-2
How to Cite
Downloads
References
Mechineni A, Kassab H, Manickam R. Remdesivir for the treatment of COVID 19: Review of the pharmacological properties, safety and clinical effectiveness. Expert Opinion on Drug Safety, 2021;20(11): 1299-1307.
DOI:10.1080/14740338.2021.1962284
Sungnak W, Huang N, Bécavin C. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. 2020;26(5):681-687.
DOI:10.1038/s41591-020-0868-6
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. Jama. 2020;324 (8):782-793.
DOI:10.1001/jama.2020.12839
World Health, Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. Retrieved from Geneva; 2020.
Available:https://apps.who.int/iris/handle/10665/332196
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Wei Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. The Lancet. 2020; 395(10223):507-513.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395 (10223):497-506.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Wong JY. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England Journal of Medicine; 2020.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239-1242.
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, Henao-Martinez AF. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Medicine and Infectious Disease. 2020;34:101623.
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Jama. 2020;323(18):1775-1776.
Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases. 2020;20(5):533-534.
Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nature Reviews Endocrinology. 2020;16 (6):297-298.
Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, Zhang Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Medicine. 2020;180(7): 934-943.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Gu X. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. The Lancet. 2020;395(10229):1054-1062.
Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, Stachel A. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clinical Infectious Diseases. 2020;71(15):896-897.
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host –virus interaction, and proposed neurotropic mechanisms. ACS Chemical Neuroscience. 2020;11(7):995-998.
Li YC, Bai WZ, Hashikawa T. Response to commentary on “The neuroinvasive potential of SARS‐CoV‐2 may play a role in the respiratory failure of COVID‐19 patients. Journal of Medical Virology. 2020; 92(7):707-709.
Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Translational Research. 2020; 220:1-13.
Mao L, Wang M, Chen S, He Q, Chang J, Hong C, Jin H. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. MedRxiv; 2020.
Ruggeri M, Signorini A, Caravaggio S, Alraddadi B, Alali A, Jarrett J, Al Musawi T. Modeling the potential impact of remdesivir treatment for hospitalized patients with COVID-19 in Saudi Arabia on healthcare resource use and direct hospital costs: A hypothetical study. Clin Drug Investig, 2022;42(8):669-678.
DOI:10.1007/s40261-022-01177-z
Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Yang C. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain, Behavior, and Immunity. 2020;87:18-22.
De Clercq E. Strategies in the design of antiviral drugs. Nature Reviews Drug Discovery. 2002;1(1):13-25.
Mehellou Y, Balzarini J, McGuigan C. Aryloxy phosphoramidate triesters: A technology for delivering monophosphorylated nucleosides and sugars into cells. ChemMedChem: Chemistry Enabling Drug Discovery. 2009; 4(11):1779-1791.
Seley-Radtke KL, Yates MK. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Research. 2018;154:66-86.
Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Ross B. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses: ACS Publications; 2017.
Cho A, Saunders OL, Butler T, Zhang L, Xu J, Vela JE, Kim CU. Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7, 9-dideazaadenosine C-nucleosides. Bioorganic & Medicinal Chemistry Letters. 2012;22(8):2705-2707.
Green N, D Ott, RJ, Isaacs R, Fang H. Cell-based assays to identify inhibitors of viral disease. Expert Opinion on Drug Discovery. 2008;3(6):671-676.
Lo MK, Feldmann F. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. 2019; 11(494).
DOI:10.1126/scitranslmed.aau9242
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15): 4773-4779.
DOI:10.1074/jbc.AC120.013056
Hu W-j, Chang L, Yang Y, Wang X, Xie Y-c, Shen J-s, Liu J. Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. Acta Pharmacologica Sinica. 2021; 42(7):1195-1200.
DOI:10.1038/s41401-020-00537-9
Zhu G, Zhu C, Zhu Y, Sun F. Minireview of progress in the structural study of SARS-CoV-2 proteins. Current Research in Microbial Sciences. 2020;1.
DOI:10.1016/j.crmicr.2020.06.003
Deval J. Antimicrobial strategies. Drugs. 2009;69(2):151-166.
Snell NJ. Ribavirin-current status of a broad spectrum antiviral agent. Expert opinion on Pharmacotherapy. 2001;2(8): 1317-1324.
Witkowski J, Robins RK, Sidwell RW, Simon LN. Design, synthesis, and broad spectrum antiviral activity of 1-. beta.-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide and related nucleosides. Journal of Medicinal Chemistry. 1972;15 (11):1150-1154.
Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin Epidemiol Glob Health. 2021;9:123-127
DOI:10.1016/j.cegh.2020.07.011
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Hui HC. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594): 381-385.
Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Central Science. 2020;6(5): 672-683.
Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences. 2020;253:117592.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Lescure F-X. Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine. 2020;382 (24):2327-2336.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Lu Q. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395(10236): 1569-1578.
Pan H, Peto R, Henao-Restrepo A-M, Preziosi M-P, Sathiyamoorthy V, Abdool Karim Q, Malekzadeh R. Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results. Lancet. 2022;399: 1941-1953.
Gupte V, Hegde R, Sawant S, Kalathingal K, Jadhav S, Malabade R, Gogtay J. Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: A retrospective analysis of active surveillance database. BMC Infect Dis. 2022;22(1):1.
DOI:10.1186/s12879-021-07004-8
Allison M. NCATS launches drug repurposing program. Nat Biotechnol. 2012;30(7):571-572. DOI:10.1038/nbt0712-571a
Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020; 52(4):583-589. DOI:10.1016/j.immuni.2020.03.007
Chen WH, Strych U. The SARS-CoV-2 Vaccine Pipeline: An Overview. 2020;7 (2):61-64.
DOI:10.1007/s40475-020-00201-6
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Nicastri E. compassionate use of remdesivir for patients with severe Covid-19. 2020;382 (24):2327-2336. DOI:10.1056/NEJMoa2007016
Hodgson J. The pandemic pipeline. Nat Biotechnol. 2020;38(5): 523-532.
DOI:10.1038/d41587-020-00005-z
Kouznetsova J, Sun W, Martínez-Romero C, Tawa G, Shinn P, Chen CZ, García-Sastre A. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect. 2014;3(12):e84.
DOI:10.1038/emi.2014.88